A colon cancer risk assessment study found that individuals who follow a healthy eating and exercise lifestyle reduce their likelihood of developing colorectal polyps or colorectal cancer.
A colon cancer risk assessment study found that individuals who follow a healthy eating and exercise lifestyle reduce their likelihood of developing colorectal polyps or colorectal cancer (CRC). The findings are important because the 27,000 individuals from around the world who responded to the survey lacked a family history of the disease.
The online survey was developed by researchers at the Cleveland Clinic to provide participants information on their CRC risk. Survey respondents gave information on personal and family history of CRC and polyps. Additionally, demographic information such as age, gender, ethnicity, height, weight, dietary factors, smoking history, and physical activity was documented.
“Colon cancer has had significant decline in the US since 1980 when colorectal cancer screening was first introduced, but these results show screening for the disease—and adherence to a healthy lifestyle—appear woefully underutilized,” said Carol A. Burke, MD, gastroenterologist at the Cleveland Clinic and the current president of the American College of Gastroenterology. Burke is a co-investigator on the survey study.
The authors found that less than 10% of respondents ate at least 5 servings of fruit, vegetables, and grains per day. Only about 25% exercised for at least a half hour, 4 times a week.
The authors also observed a gap in awareness on screening guidelines—only 36% of respondents were up to date with current CRC screening, as recommended by the US Preventive Services Task Force. A majority of those who adhered to screening guides were white, women, and had less exposure to cigarettes. Knowledge about the family history of CRC was a significant influence as well: respondents who had a first-degree relative with CRC and polyps were more likely to adhere to screening (35.7% vs 19.4%).
“Our hope by providing this online assessment is that individuals could take it, print out the results with the call to action and take it to their physicians to start the colorectal cancer screening conversation,” said Burke. The knowledge can also help physicians identify the patient population that needs to undergo screening.
The study was presented at the ongoing Digestive Disease Week 2017.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More